Whether you watched the commercials or saw President Trump speak about this this past year, you know the spiel. TrumpRx.gov will offer the cheapest prescription drugs in the world starting February 5th 2026. Trump stated that this would be “One of the greatest health care breakthroughs of our lifetime” when announcing TrumpRx.gov at the White House. Sounds nice, right? Well, the numbers don’t quite back that up for TrumpRx, and it’s important to understand what TrumpRx really means.
What TrumpRx actually is
Understanding the implications of TrumpRx is crucial for consumers looking for affordable medication.
Strip away the branding, and TrumpRx is a search portal, not a pharmacy — the government doesn’t sell or distribute any medication itself. Instead, users print a coupon and take it to a participating pharmacy, or get redirected to a drugmaker’s own direct-to-consumer website. It grew out of a September 2025 voluntary agreement with Pfizer, following a May 2025 executive order directing “most-favored-nation” (MFN) pricing — the idea that U.S. prices should match the lowest price a drugmaker charges anywhere else in the developed world.
Understanding the implications of the Trump Rx initiative and how it could affect healthcare access for Americans is essential.
The headline claim doesn’t hold up under scrutiny
This is where the “world’s lowest prices” promise runs into trouble. A New York Times investigation, done jointly with German outlets NDR and WDR, found that while the site did reduce some prices, it did not generally beat prices in other wealthy countries — and in some cases, TrumpRx prices ran twice as high. Comparing Wegovy specifically, the NYT found that TrumpRx beat Canada’s price but was still higher than in seven other countries, including Germany, Britain and Japan. For patent-protected drugs the gap was starkest: for Pfizer’s hormone drug Ngenla, Germany’s public system paid $2,723 less per two injection pens than a TrumpRx buyer would.
Reuters ran a parallel comparison against the UK’s National Health Service and found roughly a third of the 54 drugs listed on TrumpRx were actually cheaper in Britain — including Pfizer’s Xeljanz and AstraZeneca’s Farxiga, which were 67% to 82% cheaper in the UK. That’s a striking gap for a program whose entire premise is that Americans have been overcharged relative to everyone else.
There’s also a math problem. Trump has claimed some drugs are now “300% to 600%” cheaper — a claim Reuters flatly notes is mathematically impossible, since a price can only fall by up to 100%.
Who’s actually saving money — and who isn’t
The discounts that are real are concentrated in a narrow lane: obesity and fertility drugs, categories often not covered by insurance, where patients already pay cash out of pocket. Zepbound and Wegovy dropped from list prices over $1,000 a month to between $149 and $350, and EMD Serono’s fertility drugs saw an 84% discount. Those are genuine wins for a specific slice of patients.
But that’s also the catch: critics and industry observers note these are cash prices, not what most Americans actually pay through private or government insurance — and health experts have warned the site may not change what most people pay at all, since most Americans use insurance rather than paying cash. Awareness backs this up: survey data found only 7% of U.S. adults on prescription drugs had visited the site, rising to 16% among GLP-1 users — meaning the vast majority of patients this was supposedly built for haven’t used it at all. Adding to the confusion, the site offers no insurance integration, direct purchasing, or deductible tracking.
The “scam” argument — and what actually backs it
The sharpest critique isn’t just that TrumpRx underdelivers — it’s that the structure was never built to be verifiable or binding in the first place. Harvard Medical School’s Aaron Kesselheim put it plainly: the MFN deals are voluntary, carry no enforcement mechanism, and don’t address the underlying policy drivers of high U.S. drug prices, adding he wasn’t surprised the result “is something that is not workable for the vast, vast majority of patients.” A Pacific Research Institute economist — notably from a right-leaning think tank, not a partisan critic — described the program as setting only a rough ceiling on cash spending rather than genuinely making medicines more affordable.
Transparency is another sore point. KFF has noted that the details of the MFN agreements with drugmakers “remain confidential,” so very little is publicly known about what companies actually committed to — a strange feature for a program marketed on the promise of transparency. Senate Democrats, including Ron Wyden, have called for full disclosure of the negotiated terms. And the politics are hard to ignore: this rollout landed as healthcare affordability became a central issue, with Republicans fighting to hold Congress in the November midterms — a timeline that fuels suspicion the splashy launch was engineered more for headlines than for durable policy.
Meanwhile, the industry TrumpRx is supposedly squeezing hasn’t exactly suffered: pharmaceutical manufacturers spent a record $187 million on lobbying in 2025, the same year these deals were being struck.
The other side of this
To be fair to the program, it’s nothing. Even skeptical outlets acknowledge it did reduce prices on a number of drugs, and the discounts on GLP-1 and fertility medications are real dollars back in real patients’ pockets, even if that group is narrower than advertised.
The administration’s defense of the international price gaps is also worth stating on its own terms: officials told the NYT that TrumpRx prices can still be a fair deal even where the sticker price is higher, once differing national economic conditions are factored in, a point Eli Lilly echoed.
Novo Nordisk similarly argues that U.S.-to-Europe comparisons often ignore differences in dosing, approved uses, and delivery devices, which can distort apples-to-apples comparisons. And 16 of the world’s largest drugmakers signed on to the framework, a real, if voluntary, concession from an industry that has resisted price regulation for decades. Whether that amounts to genuine reform or a well-marketed half-measure is something reasonable people can disagree on — but the gap between the “world’s lowest prices” pitch and what independent analyses have found is documented, not speculative.
